Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Overview of attention for article published in Frontiers in oncology, August 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 5 X users

patent: 3 patents

Citations

dimensions_citation: 106 Dimensions

Readers on

mendeley: 75 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 15,695 followers.

@AaronGoodman33 https://t.co/wz1d005Fbx

28 May 2021

Reply Repost Favourite

- Grade 1 or 2 CRS : 25% and 50% - ORR : 81.81% - CR: 45.45%

06 Sep 2019

Reply Repost Favourite

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma https://t.co/AnqXhMEik7 #lymsm #lymphoma

06 Sep 2019

Reply Repost Favourite

RT @FrontOncology: New research: Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against R…

20 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.